Posted Fri, Jul, 12,2013
Published today in Clinical Medicine Insights: Urology is a new review by Jatinder Goyal and Emmanuel S. Antonarakis. Read more about this paper below:
Title
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
Abstract
Treatment of castration-resistant prostate cancer remains an area of unmet medical need. Evidence suggests that this entity continues to be driven by androgens and androgen receptor (AR) signaling. Abiraterone acetate, a pregnenolone derivative, is an oral selective and irreversible inhibitor of the key steroidogenic enzyme CYP17. It possesses dual 17-α hydroxylase and C17,20-lyase blocking activity, the result of which is decreased gonadal and extra-gonadal androgen synthesis. Abiraterone was first approved by the US Food and Drug Administration (FDA) in 2011 following the demonstration of superior survival compared with placebo in the post-docetaxel population. Since that time, more evidence has been generated from preclinical studies and clinical trials which have considerably enhanced our understanding of this complex disease. In this paper, we review the development of abiraterone acetate, its pharmacological characteristics, and its effects on the androgen-AR signaling axis, along with the combined experience from clinical trials. We also discuss some of the ongoing trials using this agent, as well as potential mechanisms of abiraterone resistance, novel biomarker development, and future directions using AR-directed therapies.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesI am highly impressed with the professional integrity, efficiency, and friendly communication of the editorial staff at Libertas Academia. Recently, I had an authorship issue which I brought to the attention of the Publisher and CEO (Mr. Tom Hill) of the journal Air, Soil, and Water Research. The issue was taken very seriously and was handled appropriately in an efficient and timely manner. I would like to express my sincere appreciation and utmost respect for ...
Facebook Google+ Twitter
Pinterest Tumblr YouTube